[go: up one dir, main page]

SV2009003241A - Uso de compuestos de carbamato en la elaboracion de medicamentos de eficacia para el tratamiento de trastornos de comportamiento perturbador ref. prd2755svpct - Google Patents

Uso de compuestos de carbamato en la elaboracion de medicamentos de eficacia para el tratamiento de trastornos de comportamiento perturbador ref. prd2755svpct

Info

Publication number
SV2009003241A
SV2009003241A SV2009003241A SV2009003241A SV2009003241A SV 2009003241 A SV2009003241 A SV 2009003241A SV 2009003241 A SV2009003241 A SV 2009003241A SV 2009003241 A SV2009003241 A SV 2009003241A SV 2009003241 A SV2009003241 A SV 2009003241A
Authority
SV
El Salvador
Prior art keywords
treatment
development
ref
medicines
effectiveness
Prior art date
Application number
SV2009003241A
Other languages
English (en)
Inventor
Magali Hass
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SV2009003241A publication Critical patent/SV2009003241A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN ES EL USO DE UN COMPUESTO PARA LA ELABORACIÓN DE UN MEDICAMENTO EFICAZ EN EL TRATAMIENTO DE TRANSTORNOS DE COMPORTAMIENTO PERTURBADOR INCLUYENDO TANTO TRANSTORNO DE LA CONDUCTA COMO TRANSTORNO DE OPOSICIÓN DESAFIANTE QUE COMPRENDE UNA CANTIDAD DE UNO O MÁS COMPUESTOS DE CARBAMATO DE FORMULA 1 O FÓRMULA 2, COMO SE DEFINE AQUÍ Y COMO SE MUESTRA A CONTINUACIÓN: (VER FORMULA); LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA A EL USO DE UN COMPUESTO EN LA ELABORACIÓN DE UN MEDICAMENTO EFICAZ PARA EL TRATAMIENTO DE TRANSTORNOS DE COMPORTAMIENTO PERTURBADOR INCLUYENDO TANTO TRANSTORNO DE LA CONDUCTA COMO TRANSTORNO DE OPOSICIÓN DESAFIANTE, QUE INCLUYE MONO-TERAPIA Y ALTERNATIVAMENTE CO-TERAPIA POR LO MENOS CON UN MEDICAMENTO PSICOACTIVO ADICIONAL
SV2009003241A 2006-10-27 2009-04-27 Uso de compuestos de carbamato en la elaboracion de medicamentos de eficacia para el tratamiento de trastornos de comportamiento perturbador ref. prd2755svpct SV2009003241A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86313706P 2006-10-27 2006-10-27

Publications (1)

Publication Number Publication Date
SV2009003241A true SV2009003241A (es) 2010-04-15

Family

ID=39469514

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2009003241A SV2009003241A (es) 2006-10-27 2009-04-27 Uso de compuestos de carbamato en la elaboracion de medicamentos de eficacia para el tratamiento de trastornos de comportamiento perturbador ref. prd2755svpct

Country Status (19)

Country Link
US (1) US20080103127A1 (es)
EP (1) EP2089015B1 (es)
JP (1) JP2010508279A (es)
KR (1) KR20090088379A (es)
CN (1) CN101646432A (es)
AT (1) ATE489083T1 (es)
AU (1) AU2007329779A1 (es)
BR (1) BRPI0718318A2 (es)
CA (1) CA2667510A1 (es)
CO (1) CO6160292A2 (es)
DE (1) DE602007010818D1 (es)
EA (1) EA015690B1 (es)
ES (1) ES2354319T3 (es)
IL (1) IL198396A0 (es)
MX (1) MX2009004552A (es)
NO (1) NO20091659L (es)
SV (1) SV2009003241A (es)
WO (1) WO2008070277A2 (es)
ZA (1) ZA200903652B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
TWI636784B (zh) * 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CN113993522A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗焦虑障碍、头痛病症和进食障碍的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
AU782759B2 (en) * 1999-08-20 2005-08-25 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
CZ20032311A3 (cs) * 2001-02-27 2005-02-16 Ortho-Mcneil Pharmaceutical, Inc. Karbamátová sloučenina a léčivo pro prevenci a léčení úzkosti

Also Published As

Publication number Publication date
DE602007010818D1 (de) 2011-01-05
WO2008070277A2 (en) 2008-06-12
EA200970425A1 (ru) 2009-12-30
ZA200903652B (en) 2010-08-25
MX2009004552A (es) 2009-11-10
AU2007329779A1 (en) 2008-06-12
ES2354319T3 (es) 2011-03-14
CA2667510A1 (en) 2008-06-12
EA015690B1 (ru) 2011-10-31
EP2089015A2 (en) 2009-08-19
IL198396A0 (en) 2010-02-17
CN101646432A (zh) 2010-02-10
JP2010508279A (ja) 2010-03-18
ATE489083T1 (de) 2010-12-15
KR20090088379A (ko) 2009-08-19
NO20091659L (no) 2009-05-26
BRPI0718318A2 (pt) 2013-11-26
WO2008070277A3 (en) 2008-08-07
US20080103127A1 (en) 2008-05-01
EP2089015B1 (en) 2010-11-24
CO6160292A2 (es) 2010-05-20

Similar Documents

Publication Publication Date Title
CR20110110A (es) Composicion farmaceutica
CL2017003288A1 (es) Métodos para tratar o prevenir enfermedades relacionadas con el colesterol (divisional solicitud 201303214)
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
MX2010005931A (es) Profarmacos de tetrahidrocanabinol, composiciones que comprenden profarmacos de tetrahidrocanabinol y metodos para utilizar los mismos.
BRPI0517553A (pt) mecanismo de exposição de dose para um dispositivo de distribuição de fármaco
MX380318B (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
CL2012002319A1 (es) Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras.
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
DOP2011000044A (es) Metodos para tratar la talasemia
AR054141A1 (es) Terapia combinada para el tratamiento de trastornos inmunoinflamatorios
CY1113122T1 (el) Μορφες δοσολογιας ανθεκτικες σε παραβιαση
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
SV2007002359A (es) Formas de dosificacion farmaceutica solidas administrables por via oral con liberacion modificada ref. bhco 41331/sv
ECSP088854A (es) Moduladores bencimidazolicos de vr1
GT201500092A (es) Moduladores de quinolinillo unidos a fenilo de ror-gamma-t
CO6362017A2 (es) Peptidos antivirales terapeuticos
BR112014015568A2 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
CR10422A (es) Formulaciones de dosificacion solida
BRPI0706992C8 (pt) composto de fórmula (i) e formulação farmacêutica
SV2009003241A (es) Uso de compuestos de carbamato en la elaboracion de medicamentos de eficacia para el tratamiento de trastornos de comportamiento perturbador ref. prd2755svpct
ECSP088716A (es) Medicamentos que contienen fluoroquinolonas
SV2009003247A (es) Uso de compuestos de carbamato en la elaboración de medicamentos para el tratamiento de la depresión
AR113778A2 (es) Composición farmacéutica que comprende una sal de difosfato de n-[6-(cis-2,6-dimetilmorfolin-4-il)piridin-3-il]-2-metil-4’-(trifluormetoxi)[1,1’-bifenil]-3-carboxamida
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".

Legal Events

Date Code Title Description
FD Lapse